Journal article icon

Journal article

Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer.

Abstract:

AZD3409 is an orally active double prodrug that was developed as a novel dual prenyltransferase inhibitor. The formation of the active metabolite AZD3409 acid is mediated by esterases in plasma and cells. The aim of this phase I study was to determine the maximum tolerated dose, toxicities, pharmacokinetics and pharmacodynamics of AZD3409. AZD3409 was administered orally to patients with advanced solid malignancies using an interpatient dose-escalation scheme starting at 500 mg AZD3409 once d...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1038/sj.bjc.6604402

Authors


Expand authors...
Journal:
British journal of cancer
Volume:
98
Issue:
12
Pages:
1951-1958
Publication date:
2008-06-05
DOI:
EISSN:
1532-1827
ISSN:
0007-0920
URN:
uuid:915dad03-2ace-4f41-bd4b-96ceab4e4ae6
Source identifiers:
119771
Local pid:
pubs:119771

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP